The ongoing phase 3 trial evaluating combination chemotherapy with checkpoint inhibitors as a first-line treatment in PD-L1+/HER-2− advanced GC is Keynote-062 (NCT02494583), which is divided into three groups, pembrolizumab, pembrolizumab in combination with cisplatin/5-FU, and cisplatin/5-FU alone. This evidence concerns the gene CD274 and gastric cancer.